Trials / Completed
CompletedNCT00712855
A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Phase 1B, Multi-center, Open Label, Dose Escalation Study of Mapatumumab ([HGS1012], a Fully-human Monoclonal Antibody to TRAIL-R1) in Combination With Sorafenib as a First Line Therapy in Subjects With Advanced Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Human Genome Sciences Inc., a GSK Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of escalating doses of mapatumumab in combination with sorafenib in subjects with advanced Hepatocellular Carcinoma who are positive for hepatitis B surface antigen or hepatitis C antibody.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | mapatumumab | 3, 10, or 30 mg/kg IV (in the vein), on day 1 of each 21 day cycle |
| DRUG | sorafenib | 400 mg orally, twice a day continuously in each cycle |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2011-08-01
- Completion
- 2012-08-01
- First posted
- 2008-07-10
- Last updated
- 2012-10-30
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00712855. Inclusion in this directory is not an endorsement.